BlueCross and BlueShield of Montana Medical Policy/Codes
Wireless Capsule Endoscopy as a Diagnostic Technique in Disorders of the Small Bowel, Esophagus, and Colon
Chapter: Radiology
Current Effective Date: October 18, 2012
Original Effective Date: May 01, 2006
Publish Date: October 18, 2012
Revised Dates: March 1, 2010; September 14, 2010; October 18, 2012
Description

Wireless capsule endoscopy is a device intended to visualize portions of the bowel which are not accessible via upper or lower endoscopy, primarily the small bowel. Patients swallow the capsule, and it records images of the intestinal mucosa as it passes through the gastrointestinal (GI) tract. The capsule is collected after being excreted and the images interpreted.

Wireless capsule endoscopy is performed using the PillCam™ Given® Diagnostic Imaging System (previously called M2A®), which is a disposable imaging capsule manufactured by Given Imaging, Ltd (Norcross, GA). The capsule measures 11 by 30 mm and contains video imaging, self-illumination, and image transmission modules, as well as a battery supply that lasts up to 8 hours. The indwelling camera takes images at a rate of 2 frames per second as peristalsis carries the capsule through the gastrointestinal tract. The average transit time from ingestion to evacuation is 24 hours. The device uses wireless radio transmission to send the images to a receiving recorder device that the patient wears around the waist. This receiving device also contains some localizing antennae sensors that can roughly gauge where the image was taken over the abdomen. Images are then downloaded onto a workstation for viewing and processing.

The device received marketing clearance from the U.S. Food and Drug Administration (FDA) on August 1, 2001, through the 510(k) process. The FDA clearance provides for the capsule's use "along with – not as a replacement for – other endoscopic and radiologic evaluations of the small bowel." The FDA clarified that the "capsule was not studied in the large intestine." On July 1, 2003, a supplemental 510(k) premarket notification was cleared, and the labeled indications were modified by removing the “adjunctive” use qualification: “the Given® Diagnostic System is intended for visualization of the small bowel mucosa. It may be used as a tool in the detection of abnormalities of the small bowel.”

In November 2004, the device received FDA clearance for the following labeled indication: “the Given® Diagnostic System with the PillCam™ ESO Capsule is intended for the visualization of esophageal mucosa.” A new model was cleared by the FDA in June 2007, the PillCam ES02 Capsule. In September 2007, the FDA cleared the Olympus Capsule Endoscope System through the 510(k) process for “visualization of the small intestine mucosa.” More recent versions of both these systems also incorporate a blood indicator feature to assist with rapid screening of intestinal lesions with bleeding potential.

In the small bowel, the capsule camera has been most frequently proposed as a technique to identify the source of obscure intestinal bleeding, although recently there has been interest in exploring its use in patients with inflammatory bowel disease. Alternative diagnostic techniques include barium studies or small intestinal endoscopy. In the esophagus, the capsule camera has been proposed as a screening technique for Barrett’s esophagus associated with gastroesophageal reflux disease (GERD). Evaluation of the esophagus requires limited transit time, and it is estimated that the test takes 20 minutes to perform. Alternative techniques include upper endoscopy.

In 2006, the FDA also provided clearance for the Given AGILE patency system. This system is an accessory to the PillCam video capsule and, according to FDA material, is intended to verify adequate patency of the GI tract prior to administration of the PillCam in patients with known or suspected strictures. This capsule is of similar size to the endoscopy capsule but is made of lactose and barium and dissolves within 30–100 hours of entering the GI tract. It carries a tracer material that can be detected by a scanning device. Excretion of the intact capsule without symptoms (abdominal pain or obstruction) is reported to predict the uncomplicated passage of the wireless capsule.

Policy

Prior authorization is recommended. To authorize, call Blue Cross and Blue Shield of Montana (BCBSMT) Customer Service at 1-800-447-7828 or fax your request to the Medical Review Department at 406-437-7863. A retrospective review is performed if services are not prior authorized.

Medically Necessary

Blue Cross and Blue Shield of Montana (BCBSMT) may consider wireless capsule endoscopy of the small bowel medically necessary for the following indications:

  • Initial diagnosis in patients with suspected Crohn’s disease without evidence of disease on conventional diagnostic tests such as small-bowel follow-through (SBFT) and upper and lower endoscopy.
  • Obscure gastrointestinal (GI) bleeding suspected of being of small bowel origin, as evidenced by prior inconclusive upper and lower gastrointestinal endoscopic studies performed during the current episode of illness.
  • For surveillance of the small bowel in patients with hereditary GI polyposis syndromes, including familial adenomatous polyposis and Peutz-Jeghers syndrome.

Investigational

BCBSMT considers other indications of wireless capsule endoscopy investigational, including but not limited to:

  • Evaluation of the extent of involvement of known Crohn’s disease.
  • Evaluation of the esophagus, in patients with gastroesophageal reflux (GERD) or other esophageal pathologies.
  • Evaluation of other gastrointestinal diseases not presenting with GI bleeding, including but not limited to, celiac sprue, irritable bowel syndrome, small bowel neoplasm.
  • Evaluation of the colon, including but not limited to, detection of colonic polyps or colon cancer.

BCBSMT considers the patency capsule investigational, including use to evaluate patency of the gastrointestinal tract before wireless capsule endoscopy.

Federal Mandate

Federal mandate prohibits denial of any drug, device or biological product fully approved by the FDA as investigational for the Federal Employee Program (FEP). In these instances coverage of these FDA-approved technologies are reviewed on the basis of medical necessity alone.

Policy Guidelines

Obscure GI bleeding is defined as “recurrent or persistent iron-deficiency anemia, positive fecal occult blood test, or visible bleeding with no bleeding source found at original endoscopy.” (Van Gossum 2001)

In 2004, a CPT code 91110 was introduced, which specifically describes the use of the capsule camera as follows:

91110: Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus through ileum, with physician interpretation and report.

Effective in 2007, there is a CPT code specific to capsule endoscopy of the esophagus alone:

91111: Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with physician interpretation and report.

Rationale for Benefit Administration

This medical policy was developed through consideration of peer reviewed medical literature, FDA approval status, accepted standards of medical practice in Montana, Technology Evaluation Center evaluations, and the concept of medical necessity. BCBSMT reserves the right to make exceptions to policy that benefit the member when advances in technology or new medical information become available.

The purpose of medical policy is to guide coverage decisions and is not intended to influence treatment decisions. Providers are expected to make treatment decisions based on their medical judgment. BCBSMT recognizes the rapidly changing nature of technological development and welcomes provider feedback on all medical policies.

When using this policy to determine whether a service, supply or device will be covered, please note that member contract language will take precedence over medical policy when there is a conflict.

Rationale

BCBSMT created this policy in 2006 and has updated it periodically with literature review. The most recent update covers the period of June 2011 through June 2012.

Literature Review

Obscure GI Bleeding

Obscure gastrointestinal (GI) bleeding is defined as bleeding from the GI tract that persists or recurs without an obvious etiology after imaging with upper and lower endoscopy and radiologic evaluation of the small bowel. Obscure GI bleeding is often detected by fecal occult blood testing performed for colon cancer screening, and the presence of anemia consistent with persistent blood loss. (1) Without anemia, further testing beyond upper and lower endoscopy is not warranted. Most obscure GI bleeding is due to lesions in the esophagus, stomach, and colon; 5% are due to lesions in the small intestine. Causes of obscure bleeding in the small intestine include angiodysplasia (70–80%), tumor (5–10%), and other causes (10–25%) including those related to medication, infections (tuberculosis), Crohn’s disease, Meckel’s diverticulum, Zollinger-Ellison, vasculitis, radiation enteritis, jejunal diverticula, and chronic mesenteric ischemia. (2) In patients older than age 60 years, angiodysplasia is the most likely cause, while in those younger than age 50 years, a small bowel tumor would be the most likely cause of bleeding. (3)

A 2007 position statement by the American Gastroenterological Association (AGA) states that capsule endoscopy should be the third test after upper and lower endoscopy in the evaluation of obscure GI bleeding. (1) Evidence cited in the accompanying technical review caused them to revise prior position statements in which other tests, such as bleeding scans, angiography, repeat endoscopy, enteroscopy, and enteroclysis were recommended, depending on the presence or absence of active bleeding. (4) The arguments supporting the utility of capsule endoscopy are based on several lines of evidence. Capsule endoscopy appears to have higher sensitivity of locating bleeding lesions compared to other diagnostic techniques, when diagnostic yields are compared. The technical review summarizes 10 studies in which capsule endoscopy was compared with push enteroscopy in the same patients. Capsule endoscopy located a source of bleeding in between 25-55% more patients than push enteroscopy. (4) One study by Hartmann et al. compared the findings of capsule endoscopy to what might be considered the gold standard for localizing bleeding, intraoperative endoscopy. (5) Capsule endoscopy was 95% sensitive in locating bleeding and was able to localize bleeding in a few cases in which intraoperative endoscopy was not able to. In a study by Pennazio et al. in which long term follow-up was used as the reference standard, capsule endoscopy was 89% sensitive and 95% specific in 56 patients in whom a confirmed diagnosis was obtained. (6) A “true” reference standard for obscure GI bleeding is, in fact, difficult or impossible to achieve, as the bleeding source may resolve and invasive techniques such as surgery cannot be justifiably used.

Suspected Crohn’s Disease

Crohn’s disease is an inflammatory disease of the small intestine. It is usually diagnosed with small bowel imaging studies and ileocolonoscopy. When these studies are negative or equivocal, capsule endoscopy has been proposed as a method for identifying Crohn’s disease. However, there is no single gold standard diagnostic test for Crohn’s disease; the diagnosis is based on a constellation of findings. Thus it is difficult to determine the diagnostic characteristics of various tests used to diagnose the condition and difficult to determine a single comparator diagnostic test to capsule endoscopy. An international consensus from 2009 stated that there are no validated diagnostic criteria for interpreting capsule endoscopy for a diagnosis of Crohn’s disease, thus, possibly explaining the variability of the diagnostic performance of capsule endoscopy. (7)

Nonetheless, despite the difficulties in evaluating the clinical value of capsule endoscopy in assessing suspected Crohn’s disease, findings tend to indicate that, compared with other diagnostic modalities, capsule endoscopy has an equivalent or higher yield of positive findings. An international consensus statement found 7 studies comparing capsule endoscopy to small-bowel follow-through (SBFT), 1 study comparing capsule endoscopy to magnetic resonance imaging (MRI), and 4 studies comparing capsule endoscopy to computed tomography (CT) scan. (7) The conclusion statements stated that capsule endoscopy may be superior to these alternative diagnostic tests.

The role of capsule endoscopy in established Crohn’s disease is less certain. An international consensus statement states that radiographic imaging should take precedence over capsule endoscopy because of the capability to detect obstructive strictures, extraluminal and transmural disease. (7) The consensus statement identifies some studies in which capsule endoscopy had a higher percentage of positive findings than alternative tests in patients with established Crohn’s disease, but it is not clear how these findings correlated with either symptoms or the outcome of therapeutic intervention.

Suspected Celiac Disease

Celiac disease or gluten-sensitive enteropathy, is an immune-mediated condition of the small intestine. Serologic markers of the disease have good sensitivity and specificity, but the gold standard for diagnosis of celiac disease is obtained through small-bowel biopsies obtained during endoscopy. Capsule endoscopy has been evaluated as an alternative method of diagnosing celiac disease or in assessing the extent of disease to improve management of patients.

A meta-analysis by El-Matary et al. compared the diagnostic performance of capsule endoscopy to a reference standard of duodenal biopsy. (8) The pooled analysis of 3 studies showed a sensitivity of 83% and a specificity of 98%. Another meta-analysis by Rokkas and Niv also compared the diagnostic performance of capsule endoscopy to biopsy, summarizing 6 studies that evaluated a total of 166 subjects. (9) The overall pooled sensitivity was 89% and the specificity was 95%. Capsule endoscopy was able to detect involvement of intestines beyond the duodenum; however, the clinical significance of detecting further extent of celiac disease is uncertain. Given the less than 90% sensitivity of capsule endoscopy for celiac disease, it does not appear to be an adequate alternative method of making an initial diagnosis.

The role of capsule endoscopy in established celiac disease has little evidence to assess. One study evaluated 47 patients with complicated celiac disease and found unexpected additional findings in 60% of patients, most of which were ulcerations. (10) However, the definition of “complicated” celiac disease included other factors such as evidence of blood loss, itself an indication for capsule endoscopy. The impact on patient management and outcomes is unclear.

Esophageal Conditions

Capsule endoscopy has the capability of visualizing several types of esophageal conditions. It could potentially substitute for traditional upper endoscopy for several indications and may have an advantage of comfort and convenience. However, interventional procedures and biopsies cannot be performed.

Most studies have shown that capsule endoscopy has inferior diagnostic characteristics compared to traditional upper endoscopy for a variety of esophageal conditions. A meta-analysis of 9 studies comparing capsule endoscopy to traditional endoscopy for detecting esophageal varices calculated a sensitivity of 83% and specificity of 85%. (11) Another meta-analysis of 9 studies comparing capsule endoscopy to traditional endoscopy for detecting Barrett’s esophagus showed a sensitivity and specificity of 77% and 86%, respectively. (12) The sensitivity of the test is not good enough to substitute for endoscopy.

Colon Cancer Screening

Capsule endoscopy has been investigated as a method of colon cancer screening. The test may detect precancerous polyps or actual cancer. Several studies have assessed the accuracy of capsule endoscopy for detection of colonic lesions. In the largest study of 328 patients, the sensitivity of capsule endoscopy was 64% for polyps 6 mm or larger, 73% for advanced adenoma, and 74% for cancer. (13) Other smaller studies show the sensitivity of capsule endoscopy for various types of lesions to be less than 80%. (14-16) A meta-analysis by Spada et al. of 8 studies enrolling 837 patients showed a sensitivity of 71% for polyps of any size and a specificity of 75%. (17) Almost all the existing studies evaluating capsule endoscopy for detecting colonic lesions have been done on patients with a clinical indication for colonoscopy rather than a screening population. Based on the low sensitivity for colonic polyps, capsule endoscopy is unlikely to be an effective screening test for colon cancer unless it is repeated more frequently than colonoscopy. The specificity of the test is not optimal either, meaning that patients will undergo unnecessary follow-up colonoscopy.

Hereditary GI Polyposis Syndromes

Persons with familial adenomatous polyposis and Peutz-Jeghers syndrome are at genetically high risk of small bowel polyps and tumors. Mata and colleagues studied the role of capsule endoscopy in 24 patients with hereditary GI polyposis syndromes, including familial adenomatous polyposis (n=20) or Peutz-Jeghers syndrome (n=4). (18) Compared to barium studies using small bowel enteroclysis, capsule endoscopy identified 4 additional patients with small bowel polyps, which were subsequently removed with endoscopic polypectomy. Another study by Brown et al. in 19 patients showed a greater number of polyps identified with capsule endoscopy than with barium follow-through examinations. (19) Although these studies are small, they demonstrate that capsule endoscopy can identify additional lesions in persons with disease syndromes at high risk for such lesions.

Patency Capsule

Contraindications to the use of capsule endoscopy include; known or suspected obstruction or stricture, Zenker’s diverticulum, intestinal pseudo-obstruction and motility disorders. Certain patients with known or suspected strictures of the small bowel may be at risk of retaining the capsule. Surgical removal may be necessary. There are limited data on the performance of the patency capsules proposed as a technique to evaluate patients with known or suspected strictures prior to using the wireless capsule endoscopy system. The capsule could be used either to eliminate certain patients who are considered low risk for capsule retention to further increase the safety of capsule endoscopy or to select patients at high risk for capsule retention who would otherwise not undergo capsule endoscopy. In either scenario, it needs to be determined whether the change in diagnostic strategy and ultimate treatment was ultimately improved as a consequence of either being selected or de-selected to have a capsule endoscopy.

These improvements would need to be weighed against any complications due to the use of the patency capsule. The published studies are small and do not provide comparative data about the incremental value of this capsule over standard clinical evaluation. Also, in some series, administration of the patency capsule has produced symptoms requiring hospitalization and even surgery. In a series from Europe, Delvaux et al. reported on findings in 22 patients with suspected intestinal stricture, 15 of whom had Crohn’s disease. (20) In this study, at 30 hours after ingestion, the patency capsule was detected in 17 patients (72.3 %). In all patients in whom the capsule was blocked in the small intestine, the stenosis had been suspected on computed tomography (CT) scan or small-bowel follow-through. In 3 patients, the delay in progression of the patency capsule led to cancellation of capsule endoscopy. In 3 patients, the patency capsule induced a symptomatic intestinal occlusion, which resolved spontaneously in 1 and required emergency surgery in 2. The authors commented that the current technical development of the patency capsule limits its use in clinical practice, as it did not detect stenoses undiagnosed by CT or small-bowel follow-through, and the start of dissolution at 40 hours after ingestion is too slow to prevent episodes of intestinal occlusion. They also comment that a careful interview eliciting the patient's history and symptoms remains the most useful indicator with regard to suspicion of an intestinal stenosis. In another study from Europe, Spada et al. reported on findings in 27 patients, 24 with Crohn’s disease. (21) In this study, 25 patients (92.6%) retrieved the patency capsule in the stools. Six patients complained of abdominal pain, 4 of whom excreted a nonintact capsule, and hospitalization was required in 1 patient due to occlusive syndrome.

Several studies show that patients who had uncomplicated passage of the patency capsule subsequently underwent uncomplicated capsule endoscopy. (22-24) These patients often had significant findings on capsule endoscopy. (22,23) However, it is difficult to determine whether the findings of capsule endoscopy in these patients improved their outcomes beyond any alternate test regimen that could have been done. In 1 of these studies, 3 of 106 patients had severe adverse events, including 1 patient who required surgery. (22) The overall balance of harm and benefit of using the patency capsule cannot be determined from the existing studies.

Summary

Wireless capsule is a device that allows visualization of intestinal mucosa that is not accessible by traditional upper or lower endoscopy. It has been most extensively studied in patients with obscure GI bleeding. For this population, the evidence demonstrates that capsule endoscopy can identify a bleeding source in a substantial number of patients who are unable to be diagnosed by other methods, with a low incidence of adverse events. Since there are no other options for diagnosing obscure small bowel bleeding in patients who have negative upper and lower endoscopy, this technique will likely improve health outcomes by directing specific treatment when a bleeding source is identified. Therefore wireless capsule endoscopy may be considered medically necessary for the evaluation of obscure GI bleeding.

Similarly, for patients with suspected small bowel Crohn’s disease and for patients with familial polyposis syndromes who require surveillance, other methods are not available for visualizing the small bowel. Although the performance characteristics of the capsule for these indications are uncertain, it is likely to improve health outcomes by identifying some cases of these disorders and directing specific treatment. Therefore, wireless capsule endoscopy may be considered medically necessary for these indications.

For other conditions, including determining the extent of involvement in Crohn’s disease, celiac disease, esophageal conditions, colon cancer screening, and for determination of patency of the GI tract, the evidence is not sufficient to conclude that health outcomes are improved. For some of these conditions, e.g., esophageal conditions and colon cancer screening, other modalities are available that are superior to capsule endoscopy. For other conditions, e.g., determining the extent of Crohn’s disease, the accuracy of the device needs to be established prior to determining whether outcomes are improved. For these reasons, wireless capsule endoscopy is considered investigational for these indications.

Practice Guidelines and Position Statements

A 2007 position statement by the American Gastroenterological Association (AGA) (1) states the following concerning obscure GI bleeding and capsule endoscopy:

  • Evaluation of the patient with obscure GI bleeding is dependent on the extent of the bleeding and the age of the patient.
  • Patients with occult GI blood loss and no anemia most likely do not require evaluation beyond colonoscopy unless upper tract symptoms are present.
  • Patients with occult GI blood loss and iron deficiency anemia and negative workup on esophagogastroduodenoscopy (EGD) and colonoscopy need comprehensive evaluation, including capsule endoscopy to identify an intestinal bleeding lesion.

An international consensus panel from 2009 (7) published guidelines on the use of wireless capsule endoscopy for inflammatory bowel disease (IBD). These guidelines included the following statements about evaluation of Crohn’s disease:

  • Small bowel capsule endoscopy is able to identify mucosal lesions compatible with Crohn’s disease in some patients in whom conventional endoscopic and small-bowel radiographic imaging modalities have been nondiagnostic.
  • A diagnosis of Crohn’s disease should not be based on the appearances at capsule endoscopy alone.
  • A normal capsule endoscopy has a high negative predictive value for active small-bowel Crohn’s disease.
  • For patients with established Crohn’s disease, small bowel capsule endoscopy is better at identifying small-bowel mucosal lesions than barium and may be better than CT or MR enterography or enteroclysis, but the clinical significance of this potential difference remains to be defined.
  • There are no validated diagnostic criteria for small bowel capsule endoscopy for the diagnosis of Crohn’s disease.
ICD-9 Codes

211.2, 555.0 – 555.9, 578.0 – 578.9, 759.6

ICD-10 Codes
D13.2-D13.39, K50.00-K50.919, K92.0-K92.2, Q85.0-Q85.9  
Procedural Codes: 91110, 91111
References
  1. Raju GS, Gerson L, Das A et al. American Gastroenterological Association (AGA) Institute medical position statement on obscure gastrointestinal bleeding. Gastroenterology 2007; 133(5):1694-6.
  2. Zuckerman GR, Prakash C, Askin MP et al. American Gastroenterological Association Practice Guidelines. AGA technical review on the evaluation and management of occult and obscure gastrointestinal bleeding. Gastroenterology 2000; 118(1):201-21.
  3. Lewis BS. Small intestinal bleeding. Gastroenterol Clin North Am 2000; 29(1):67-95.
  4. Raju GS, Gerson L, Das A et al. American Gastroenterological Association (AGA) Institute technical review on obscure gastrointestinal bleeding. Gastroenterology 2007; 133(5):1697-717.
  5. Hartmann D, Schmidt H, Bolz G et al. A prospective two-center study comparing wireless capsule endoscopy with intraoperative enteroscopy in patients with obscure GI bleeding. Gastrointest Endosc 2005; 61(7):826-32.
  6. Pennazio M, Santucci R, Rondonotti E et al. Outcome of patients with obscure gastrointestinal bleeding after capsule endoscopy; report of 100 consecutive cases. Gastroenterology 2004; 126(3):643-53.
  7. Bourreille A, Ignjatovic A, Aabakken L et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy 2009; 41(7):618-37.
  8. El-Matary W, Huynh H, Vandermeer B. Diagnostic characteristics of given video capsule endoscopy in diagnosis of celiac disease: A meta-analysis. J Laparoendosc Adv Surg Tech A 2009: 19(6):815-820.
  9. Rokkas T, Niv Y. The role of video capsule endoscopy in the diagnosis of celiac disease: a meta-analysis. Eur J Gastroenterol Hepatol 2012; 24(3):303-8.
  10. Culliford A, Daly J, Diamond B et al. The value of wireless capsule endoscopy in patients with complicated celiac disease. Gastrointest Endosc 2005; 62(1):55-61.
  11. Guturu P, Sagi SV, Ahn D et al. Capsule endoscopy with PILLCAM ESO for detecting esophageal varices: a meta-analysis. Minerva Gastroenterol Dietol 2011; 57(1):1-11.
  12. Bhardwaj A, Hollenbeak CS, Pooran N et al. A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett's esophagus in patients with gastroesophageal reflux disease. Am J Gastroenterol 2009; 104(6):1533-9.
  13. Van Gossum A, Navas MM, Fernandez-Urien I et al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med 2009; 361(3):264-70.
  14. Eliakim R, Fireman Z, Gralnek IM et al. Evaluation of the PillCam Colon capsule in the detection of colonic pathology: results of the first multicenter, prospective, comparative study. Endoscopy 2006; 38(10):963-70.
  15. Schoofs N, Devière J, Van Gossum A. PillCam colon capsule endoscopy compared with colonoscopy for colorectal tumor diagnosis: a prospective pilot study. Endoscopy 2006; 38(10):971-7.
  16. Pilz JB, Portmann S, Peter S et al. Colon capsule endoscopy compared to conventional colonoscopy under routine screening conditions. BMC Gastroenterol 2010; 10:66.
  17. Spada C, Hassan C, Marmo R et al. Meta-analysis shows colon capsule endoscopy is effective in detecting colorectal polyps. Clin Gastroenterol Hepatol 2010; 8(6):516-522
  18. Mata A, Llach J, Castells A et al. A prospective trial comparing wireless capsule endoscopy and barium contrast series for small-bowel surveillance in hereditary GI polyposis syndromes. Gastrointest Endosc 2005; 61(6):721-5.
  19. Brown G, Fraser C, Schofield G et al. Video capsule endoscopy in Peutz-Jeghers syndrome: a blinded comparison with barium follow-through for detection of small-bowel polyps. Endoscopy 2006; 38(4):385-90.
  20. Delvaux M, Ben Soussan E, Laurent V et al. Clinical evaluation of the use of the M2A patency capsule system before a capsule endoscopy procedure, in patients with known or suspected intestinal stenosis. Endoscopy 2005; 37(9):801-7.
  21. Spada C, Shah SK, Riccioni ME et al. Video capsule endoscopy in patients with known or suspected small bowel stricture previously tested with the dissolving patency capsule. J Clin Gastroenterol 2007; 41(6):576-82.
  22. Herrerias JM, Leighton JA, Costamagna G et al. Agile patency system eliminates risk of capsule retention in patients with known intestinal strictures who undergo capsule endoscopy. Gastrointest Endosc 2008; 67(6):902-9.
  23. Postgate AJ, Burling D, Gupta A et al. Safety, reliability and limitations of the given patency capsule in patients at risk of capsule retention: a 3-year technical review. Dig Dis Sci 2008; 53(10):2732-8.
  24. Banerjee R, Bhargav P, Reddy P et al. Safety and efficacy of the M2A patency capsule for diagnosis of critical intestinal patency: results of a prospective clinical trial. J Gastroenterol Hepatol 2007; 22(12):2060-3.
History
October 2012  Policy revised with literature search; rationale extensively revised and condensed. References 1, 4, 6, 9, 10, 15, 17 added. No changes to policy statements. 
BCBSMT Home
®Registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. ®LIVE SMART. LIVE HEALTHY. is a registered mark of BCBSMT, an independent licensee of the Blue Cross and Blue Shield Association, serving the residents and businesses of Montana.
CPT codes, descriptions and material only are copyrighted by the American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS Restrictions Apply to Government Use. CPT only © American Medical Association.
Wireless Capsule Endoscopy as a Diagnostic Technique in Disorders of the Small Bowel, Esophagus, and Colon